COLL Collegium Pharmaceutical, Inc.
Legal ·
The drugmaker ends its Nucynta license and royalties with Grünenthal and gets certain patents assigned to it. Grünenthal has filed a motion to dismiss the New Jersey case.
Collegium will pay Grünenthal $17,000,000 to end a February 2026 patent suit and a Nucynta license that carried royalties. The 8-K does not say what those royalties cost the company.
Collegium paid about $650 million in cash for AZSTARYS, using about $350 million of cash on hand and a $300 million delayed draw term loan. Two senior executives are leaving, and the company may pay up to $135 million more if AZSTARYS hits milestones.
Collegium paid about $650 million in cash for AZSTARYS, using $350 million of its own cash and a $300 million loan draw. Corium Therapeutics may receive up to $135 million more if milestones are met.
The five-year facility has a $580 million initial term loan, a $300 million delayed draw term loan and a $100 million revolver, with Truist Bank as administrative agent. Collegium used the initial loan to repay its previous term loan in full, including its prepayment premium, which the filing does not size.
The $980 million facility matures in 2030 and includes a $580 million initial term loan, a $300 million delayed draw term loan and a $100 million revolver. The initial term loan repaid about $581 million owed to Pharmakon, so it brought no new cash at closing.
The board approved the program on July 1, 2025. It runs through December 31, 2026 and will be funded from existing cash on hand, but the 8-K gives no cash balance to measure that against.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $780.6 million | $631.4 million |
| Research and development | $0 | |
| Net income (loss) | $62.9 million | $69.2 million |
| Cash from operations | $329.3 million | $205.0 million |
| Cash and equivalents | $231.3 million | $70.6 million |
| Short-term investments | $155.4 million | $92.2 million |
Our latest story on this, dated Oct 19, 2026: "Collegium settles Grünenthal patent suit over Nucynta ER generic for $17,000,000". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 19, 2026: "Collegium settles Grünenthal patent suit over Nucynta ER generic for $17,000,000". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 7, 2025: "Collegium Pharmaceutical authorizes buyback of up to $150 million". The story links the filing or release it is based on. Read the story.
Collegium Pharmaceutical, Inc. trades under the ticker COLL on NASDAQ.
Collegium Pharmaceutical, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:354; LS:A14SUV; LSX:A14SUV.
The SEC Central Index Key (CIK) for Collegium Pharmaceutical, Inc. is 1267565. Its filings are on SEC EDGAR.
32,555,613 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Collegium Pharmaceutical, Inc. under United States.
Our directory classifies Collegium Pharmaceutical, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Collegium Pharmaceutical, Inc. is US19459J1043.
aibio.space lists Collegium Pharmaceutical, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as VA.
$780.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Collegium Pharmaceutical, Inc. reported net income of $62.9 million for the fiscal year ended Dec 31, 2025, and generated $329.3 million of cash from operations, per its annual report to the SEC.
$129.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,5.02,7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,3.02,7.01,9.01). Source
Announced a share repurchase program. SEC Form 8-K (Items 8.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio